JNJ

On Tuesday morning's Squawk on the Street, Jim Cramer told viewers to step in on a mid-session drop in Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction).

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).

JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.

Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

Johnson & Johnson is rated HOLD for the next 6-12 months, with balanced risk, as its drug portfolio offsets Stelara losses, but MedTech remains a weak growth engine. JNJ's valuation is above historical averages, already pricing in competent execution; further upside requires clear evidence of accelerating growth in both Innovative Medicine and MedTech. Free cash flow and profitability remain strong, but dividends and buybacks exceeded free cash flow, and recent acquisitions have yet to demonstrate commercial validation.

Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.

JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the one event that could reverse both trends is now closer than most investors expect.

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.